Assessment of anti-HBs antigen in 6- to 9-year-old children routinely vaccinated via vaccination program in Iran

Medical Principles and Practice

Volumn 16, Issue 4, 2007, Pages 306-309

  Hadi, Nahal ^a,b   Hadi, Negin ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti HBV antigen; Children; Hepatitis; Iran; Vaccination

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; SEX RATIO; VACCINATION;

CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IRAN; MALE; TIME FACTORS;

EID: 34249814624     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102154     Document Type: Article

References (17)

1. Knipe DM, Howley PM (eds): Fundamental Virology, ed 4. Philadelphia, Lippincot, Williams & Wilkins, 2001, pp 1285-1318.
2. Zali MR, Mohammad K, Farhadi A, Masjedi MR, Zargar A, Noroozi A: Epidemiology of hepatitis B in the Islamic Republic of Iran. East Mediterr Health J 1996;2:290-298.
3. Shamszad M, Farzadgan H: Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iran Med Council 1982;8:238.
4. Jilg W, Lorbee B, Schmidt M, Wilske B, Zoulek G, Deinhard T: Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984;ii:1174-1175.
5. Qirbi N, Hall AJ: Epidemiology of hepatitis B in the Middle East. East Mediterr Health J 2001;6:1034-1045.
6. Nedelcu I, Gacium D, Tardei G, Ruta SM: Assessment of the anti-hepatitis B vaccination efficacy in high risk children. Rom J Virol 1998;49:4351.
7. Galimska J: Epidemiological section, Ministry of Health and Social Welfare. The Expanded Program on Immunization Calendar in Poland. Vaccine 2000;18(suppl 18):1541-1543.
8. Dienstag JL, Isselbacher KJ: Acute viral hepatitis; in Braunwald E, Wonsiewicz M, Englis MR (eds): Harrison's Principles of Internal Medicine, ed 15. New York, McGraw-Hill, 2001, vol 2, pp 1723-1724.
9. Hyams K: Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
10. Advances in Viral Hepatitis. Report of the WHO Expert Committee on Viral Hepatitis. World Health Organ Tech Rep Ser 1977; No 602.
11. Hepatitis B surface antigen assays: operational characteristics (phase 1). Report 2. Geneva, World Health Organization, 2004. www.who.int/ehtl.
12. Milne A, Mimitrakakis M, Allwood G, Lucas R, Moyes C, Pearce N: Immunogenicity of low doses of hepatitis B vaccine in children: a study in 650 New Zealand children. J Med Virol 1987;23:401-405.
13. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ: The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001;19:3919-3926.
14. Bonanni P, Colombai R, Gasparini R, Lo Nostro A, Tiscione E, Tomei A, Montomoli E, Comodo N: Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr Infect Dis J 1999;18:677-682.
15. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988;66:443-455.
16. Xu ZY, Liu CB, Francis DP, Purcell RH, Gun ZL, Duan SC, Chen RJ, Margolis HS, Huang CH, Maynard JE: Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine:preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-718.
17. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W: Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med 1984;311:496-501.